CHS 10 Years Impact Report

Over 7 Million People Reached by CHS since 2010

In collaboration with Kenya’s Ministry of Health and various county governments, we have supported the provision of quality HIV and TB prevention, treatment and care services across Kenya’s 47 counties since October 2010.

Corporate Highlights

CHS, Kenya’s Leading NGO in the Fight Against HIV and AIDS

CHS was named Kenya’s leading NGO in the fight against HIV/AIDS and among leading NGO sector players by the Kenya’s Nongovernmental Organisation (NGO) Coordination Board.

CHS Launches an Adolescent Adherence Mobile Application - Heroes App

With a commitment to improving treatment outcomes among adolescents living with HIV, CHS created and successfully launched a virtual plat- form dubbed the “Heroes App”.

CHS Shines at the Africa Leadership Awards

CHS received the 2017 NGO Leadership Award for its exemplary work in HIV/AIDS, while CHS Chief Executive Officer Dr Paul Wekesa, received the award for CEO of the Year in the Africa Healthcare Leadership Award category during the 2017 African Leadership Awards

Focus Area: HIV/AIDS

Strengthening Health Systems for the Provision of HIV Testing and Prevention Services

CHS supports the country’s efforts to improve the health and wellbeing of its citizens by increasing the number aware of their HIV status, ensuring those who test positive are linked to care and those that test negative have access to information that ultimately helps them make informed decisions about HIV prevention options.

Over 7.1 Million HIV Tests Done
103,138 PLHIV Identified
88,578 People Provided with ART

CHS is currently taking care of approximately 16% (177,626) People Living with HIV in Kenya on ART

Eliminating Mother to Child Transmission of HIV: Safeguarding Future Generations

Nationally, progress towards the elimination of mother to child transmission of HIV has been noted with the Prevention of Mother to Child Transmission (PMTCT) coverage increasing from 23% in 2015 to 76% in 2017 and the EMTCT rate declining from 29.7% to 11.5% during the same period.

591,060 Pregnant Women Tested and Results Received
19,001 Pregnant Women diagnosed with HIV and put on treatment
Over 2,000 Infants tested negative for HIV
Over 6,000 Infants started on ARV prophylaxis

Integrated HIV Prevention and Treatment Services for Key Populations

The World Health Organisation describes Key Populations (KP) as those that are more vulnerable and most-at-risk of HIV infection owing to either their lifestyle, profession or physiology. These include: men who have sex with men, sex workers, injecting drug users and transgender persons. Globally, key populations make up a small proportion of the general population, but they are at an extremely high risk of HIV infection.

Sexual and Gender Based Violence Care

CHS has supported 48,691 victims of SGBV through; health care worker mentorship to ensure proper documentation and care for victims, awareness creation and enhanced community based protection systems to improve GBV response and protection of victims. Additionally, CHS has established a one stop centre in Siaya County Referral Hospital whereby victims of sexual violence receive all services including, counselling, clinical assessment and legal assistance.

Staying the Course of HIV Treatment: Undetectable = Untransmittable

People living with HIV receiving effective antiretroviral treatment cannot transmit HIV sexually. Sustained antiretroviral therapy reduces the amount of HIV in the (viral load) to levels that are undetectable by a standard laboratory test, scientifically for as long as these levels are Undetectable then the virus is Untransmittable sexually.

Voluntary Medical Male Circumcision for HIV Prevention

Among the target population in Siaya County where CHS supports provision of VMMC services across all of Siaya’s six sub counties, the VMMC team successfully provided VMMC services to 140,460 men


Focus Area: Tuberculosis

Promoting Access to High Quality Patient-Centred TB Services

In efforts to reduce the incidence and TB related morbidity and mortality in Kenya, CHS continued supporting the Ministry of Health’s National Tuberculosis, Leprosy and Lung Disease Program (NTLD-Program), through the United States Agency for International Development (USAID) funded Tuberculosis Accelerated Response and Care II activity (TB ARC II)

Using Technology to Find Tuberculosis

CHS has scaled up access and use of safe, efficient and quality assured technologies to promote TB diagnosis. GeneXpert (efficient and accurate technology that tests for TB and its drug resistant variant in two hours) is the test of choice for all presumptive TB cases as per the revised National TB screening and diagnostic algorithm.

Over 649,00 Drug Sensitive Individuals Diagnosed and put on Treatment
Over 1.3 Million Samples Transported

Increasing TB Awareness and Demand for TB Screening Services

CHS worked collaboratively with the National TB Program to increase TB awareness and demand for screening services through information sharing campaigns across various information sharing platforms.

Laboratory Services

CHS has in place systems to ensure that laboratories within the network of supported facilities provide timely, quality assured, reliable and safe services. This is done through proficiency testing for services providers, trainings on biosafety and biosecurity, distribution of test kits, as well as mentorship of county health workers.

CHS 10 Years Impact Report

Read and download the entire report by clicking the button below.